Redefining Parkinson’s Treatment with Dual-Action Molecular Glues
3:00 pm - Wednesday 28th January 2026
- Dual actions on key pathogenic drivers – simultaneously degrading ZFP91 to suppress inflammation and blocking alpha-synuclein aggregation
- From neuroprotection to functional recovery – demonstrated broad beneficial effects in cognition and motor outcomes
- Validated across multiple models of neurodegeneration – robust and reproducible biological actions confirmed in vitro and in vivo
